Activation of cytokines as a mechanism of disease progression in heart failure

The scientific quest for the basic mechanism(s) responsible for the development and progression of congestive heart failure in humans has been practically exhaustive; none the less, the mechanisms responsible for the decompensation of myocardial function after myocardial injury or haemodynamic overloading, or both, have remained elusive. Initially clinicians viewed heart failure as a problem of excessive salt and water retention that was caused by abnormalities of renal blood flow (the cardiorenal model). As clinicians began to perform careful haemodynamic measurements, it also became apparent that heart failure was accompanied by reduced cardiac output and excessive peripheral vasoconstriction. This led to the development of a cardiocirculatory or haemodynamic model for heart failure, in which heart failure was thought to arise from abnormalities of the pumping capacity of the heart. Neither of these models explained the progression of heart failure. Subsequently neurohormones were considered to lead to disease progression through myocyte loss, progressive myocardial fibrosis, as well as salt and water retention. More recently, it has become evident that another class of biologically active molecules, generally referred to as cytokines are also important in heart failure.1-8 The term cytokine is applied to a group of relatively small molecular weight protein molecules (generally 15–30 kDa) that are secreted by cells in response to a variety of different inducing stimuli. Classically, cytokines are thought to be secreted by neighbouring “producer cells” and to act in an autocrine, juxtacrine or paracrine manner to influence the biological behaviour of neighbouring “target cells” (see Mann and Young8 for a brief review). However, when cytokines are overproduced they can “spill over” into the peripheral circulation where they can exert endocrine-like effects. It should be recognised that although cytokines are similar in many respects to polypeptide hormones, cytokines can be produced by a variety of different cell …

[1]  D. Mann,et al.  Expression and functional significance of tumor necrosis factor receptors in human myocardium. , 1995, Circulation.

[2]  T. LeJemtel,et al.  Pathophysiological Correlates of Increased Serum Tumor Necrosis Factor in Patients With Congestive Heart Failure: Relation to Nitric Oxide‐Dependent Vasodilation in the Forearm Circulation , 1994, Circulation.

[3]  J E Parrillo,et al.  A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. , 1989, The New England journal of medicine.

[4]  J. Kovacs,et al.  The cardiovascular response of normal humans to the administration of endotoxin. , 1989, The New England journal of medicine.

[5]  F. Pagani,et al.  Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs. , 1992, The Journal of clinical investigation.

[6]  H. Oral,et al.  Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). , 1996, Journal of the American College of Cardiology.

[7]  H. Cohen,et al.  Tumor necrosis factor, natural killer activity and other measures of immune function and inflammation in elderly men with heart failure. , 1995, Gerontology.

[8]  J. Tavernier,et al.  Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. , 1987, The Journal of biological chemistry.

[9]  N. Takahashi,et al.  Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes. , 1995, The Journal of clinical investigation.

[10]  A. Oliff,et al.  Tumors secreting human TNF/cachectin induce cachexia in mice , 1987, Cell.

[11]  AlbertSchömig,et al.  Cardiac Release of Cytokines and Inflammatory Responses in Acute Myocardial Infarction , 1995 .

[12]  J. McMurray,et al.  Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. , 1991, British heart journal.

[13]  D. Mann,et al.  Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart , 1996 .

[14]  G. MacGowan,et al.  Circulating interleukin-6 in severe heart failure. , 1997, The American journal of cardiology.

[15]  T. LeJemtel,et al.  Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. , 1996, Journal of the American College of Cardiology.

[16]  D. Fukai,et al.  Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. , 1995, The American journal of cardiology.

[17]  P. Ponikowski,et al.  Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. , 1997, Circulation.

[18]  C. Lavie,et al.  The clinical relevance of circulating tumor necrosis factor-alpha in acute decompensated chronic heart failure without cachexia. , 1996, Chest.

[19]  J. A. Bowers,et al.  Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation. , 1997, Journal of the American College of Cardiology.

[20]  O. Febo,et al.  Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. , 1995, Circulation.

[21]  G. Morris,et al.  Tumour necrosis factor alpha in severe congestive cardiac failure. , 1993, British heart journal.

[22]  L. Vaca,et al.  Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. , 1993, The Journal of clinical investigation.

[23]  H. Oral,et al.  Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. , 1997, Circulation research.

[24]  A. Matsumori,et al.  Increased circulating cytokines in patients with myocarditis and cardiomyopathy. , 1994, British heart journal.

[25]  M. Singer,et al.  TUMOUR NECROSIS FACTOR IN BRONCHOPULMONARY SECRETIONS OF PATIENTS WITH ADULT RESPIRATORY DISTRESS SYNDROME , 1989, The Lancet.

[26]  H. Oral,et al.  Tumor necrosis factor-alpha and the failing human heart. , 1995, Clinical cardiology.

[27]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[28]  H. Oral,et al.  Tumor necrosis factor-α and failing human heart , 1995 .

[29]  A. Katz,et al.  The failing heart: adaptation and deadaptation , 1983 .

[30]  S Sasayama,et al.  Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. , 1994, Circulation.

[31]  D. Hossfeld,et al.  TNF-induced cardiomyopathy , 1990, The Lancet.

[32]  P. Poole‐Wilson,et al.  Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. , 1997, The American journal of cardiology.

[33]  Simon C Watkins,et al.  Negative inotropic effects of cytokines on the heart mediated by nitric oxide. , 1992, Science.

[34]  M. Herold,et al.  Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha. , 1993, Journal of the American College of Cardiology.

[35]  M. Takemura,et al.  Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. , 1997, Journal of the American College of Cardiology.

[36]  A. Ogata,et al.  Hypoxic stress induces cardiac myocyte-derived interleukin-6. , 1995, Circulation.

[37]  J. Lancaster,et al.  Inhibition of target cell mitochondrial electron transfer by tumor necrosis factor , 1989, FEBS letters.

[38]  M. Munger,et al.  Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 1996, The American journal of cardiology.

[39]  G. Schreiner,et al.  Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Impairment of signal transduction. , 1990, Circulation research.

[40]  D. Mann,et al.  Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. , 1994, Chest.

[41]  H. Dockrell The Cytokine Handbook , 1993 .